Provided by Tiger Fintech (Singapore) Pte. Ltd.

Denali Therapeutics Inc.

16.30
+0.35002.19%
Pre-market: 16.28-0.0200-0.12%08:00 EST
Volume:1.32M
Turnover:21.45M
Market Cap:2.37B
PE:-6.34
High:16.42
Open:16.06
Low:15.65
Close:15.95
Loading ...

Denali Therapeutics Announces Topline Results for Regimen G Evaluating Eif2b Agonist Dnl343 in the Phase 2/3 Healey ALS Platform Trial

THOMSON REUTERS
·
07 Jan

Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

GlobeNewswire
·
07 Jan

Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic

Benzinga
·
04 Jan

Denali Therapeutics Initiated at Outperform by William Blair

Dow Jones
·
03 Jan

Denali Therapeutics upgraded to Buy from Hold at Stifel

TipRanks
·
17 Dec 2024

Stifel Nicolaus Upgrades Denali Therapeutics to Buy From Hold, Raises Price Target to $37 From $28

MT Newswires Live
·
16 Dec 2024

We're Hopeful That Denali Therapeutics (NASDAQ:DNLI) Will Use Its Cash Wisely

Simply Wall St.
·
09 Dec 2024

Why Is Denali Therapeutics (DNLI) Down 21.2% Since Last Earnings Report?

Zacks
·
07 Dec 2024

Denali Starts Dosing in Phase II Parkinson's Disease Study

Zacks
·
06 Dec 2024

Denali Therapeutics announces first patient dosed in Phase 2a study of BIIB122

TIPRANKS
·
05 Dec 2024

Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of Lrrk2 Inhibitor, Biib122, in Lrrk2-Associated Parkinson’s Disease

THOMSON REUTERS
·
05 Dec 2024

Denali Q3 Earnings Miss Estimates, Pipeline Progress Encouraging

Zacks
·
08 Nov 2024

Denali Therapeutics (DNLI) Receives a Hold from Stifel Nicolaus

TIPRANKS
·
07 Nov 2024

Denali Therapeutics Inc : Wedbush Raises Target Price to $33 From $30

THOMSON REUTERS
·
07 Nov 2024

BRIEF-Denali Therapeutics Q3 Net Income USD -107.192 Million

Reuters
·
07 Nov 2024

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
31 Oct 2024